Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33519
Title: Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer.
Austin Authors: Poh, Ashleigh;Sammour, Abdelaziz;Mathai, Jared;Peverall, Joanne;Van Vliet, Chris;Asadi, Khashayar ;Parakh, Sagun 
Affiliation: Olivia Newton-John Cancer Wellness and Research Centre
Medical Oncology
PathWest, Department of Diagnostic Genomics, QEII Medical Centre, Nedlands, Western Australia, Australia.
Pathology
La Trobe University School of Cancer Medicine, Bundoora, Victoria, Australia.
Issue Date: 31-Jul-2023
Date: 2023
Publication information: Journal of Thoracic Disease 2023-07-31; 15(7)
Abstract: We performed a retrospective analysis to determine the incidence of neurotrophic tropomyosin-receptor kinase (NTRK) fusion in non-small cell lung cancer (NSCLC). Archival NSCLC tissues between 2018-2020 were screened by immunohistochemistry (IHC) with IHC-positive cases undergoing confirmatory molecular analysis. Correlative clinicopathologic parameters were collected. Of 289 samples analyzed, 10 (3.5%) cases had NTRK expression on IHC. The median age of patients with NTRK-positivity on IHC was 74.9 (range, 44-88) years and 70% had a smoking history. The cohort included seven adenocarcinomas and one each squamous cell carcinoma, large-cell neuroendocrine and not otherwise specified histologies. PDL1 expression was ≤50% in five cases. Concurrent EGFR mutations were detected in three cases, with two cases also showing a PIK3CA E542K mutation and MET amplification, respectively. Due to insufficient tumor material, RNA-sequencing was undertaken in only one IHC-positive case, with the other nine cases analyzed by Fluorescent in-situ Hybridisation. A NTRK fusion, EML4-NTRK3 gene fusion was detected in one patient, a frequency of 0.35%. NTRK fusions in NSCLC are rare. This study highlights real world diagnostic challenges regarding NTRK testing, such as requirements of adequate tumor tissue and appropriate testing methodologies.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33519
DOI: 10.21037/jtd-23-113
ORCID: 
Journal: Journal of Thoracic Disease
Start page: 3811
End page: 3817
PubMed URL: 37559603
Type: Journal Article
Subjects: Neurotrophic tropomyosin-receptor kinase (NTRK)
fluorescence in situ hybridization (FISH)
immunohistochemistry (IHC)
incidence
non-small cell lung cancer (NSCLC)
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Jul 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.